Paving roads for new drugs in oncology

Area of Science:

• Oncology Drug Development
• Pharmacology
• Biotechnology

Background:

• Drug development is costly and inefficient, with low success rates from pre-clinical stages to market approval.
• The oncology drug development pipeline faces significant hurdles, impacting the timely delivery of new cancer therapies.
• Current drug discovery processes are lengthy and expensive, necessitating innovative approaches to improve efficiency.

Purpose of the Study:

• To discuss challenges in the oncology drug development critical path.
• To explore the impact of regulatory guidelines (FDA, EMEA) and microdosing studies (Phase 0 trials) on drug development.
• To review novel strategies for identifying therapeutic targets, repurposing existing drugs, and leveraging advanced technologies for personalized oncology therapy.

Main Methods:

• Review of regulatory guidelines from the FDA and EMEA.
• Analysis of microdosing studies (Phase 0 trials) for early drug development decision-making.
• Exploration of high-throughput technologies, gene therapy, and genomics for personalized medicine.

Main Results:

• Microdosing studies can inform drug development and compress timelines, aiding decisions on advancing compounds to clinical trials.
• Identifying novel molecules involved in cell death pathways and repurposing old drugs for new indications can revitalize therapeutic options.
• Revolutionary advances in high-throughput screening, gene therapy, and genomics offer potential for developing personalized cancer treatments.

Conclusions:

• Optimizing the drug development critical path in oncology requires strategic use of regulatory insights and early-phase studies.
• Novel approaches, including target identification, drug repurposing, and advanced biotechnologies, are crucial for advancing personalized oncology therapies.
• The evolution of drug discovery from traditional methods to precision medicine, informed by genomics and innovative technologies, is reshaping cancer treatment.